瘦素对高血压肾损害相关机制的研究进展

doi:10.3969/j.issn.1000-8535.2018.01.032

广州医药 ›› 2018, Vol. 49 ›› Issue (1): 110-113.DOI: 10.3969/j.issn.1000-8535.2018.01.032

瘦素对高血压肾损害相关机制的研究进展

赵位昆¹, 徐彤彤¹, 胡迪聃¹, 张向宇¹, 吕祥威²

1 桂林医学院附属医院中西医结合病区(桂林 541001);
2 广西医科大学研究生院(南宁 530021)

收稿日期:2017-09-19 出版日期:2018-01-20 发布日期:2021-12-01
通讯作者: 徐彤彤,E-mail:xutongtongguilin@163.com
基金资助:
国家自然科学基金资助项目(81760861);广西科学研究与技术开发计划项目(桂科能1598025-29);桂林市科学研究与技术开发计划项目(20130120-1)

Advances in research on the mechanism of leptin on hypertensive renal damage

ZHAO Weikun¹, XU Tongtong¹, HU Didan¹, ZHANG Xiangyu¹, LV Xiangwei²

1 Integrated traditional Chinese and Western Medicine Ward, Affiliated Hospital of Guilin Medical University, Guilin 541001, China
2 Guangxi Medical University, Nanning 530021,China

Received:2017-09-19 Online:2018-01-20 Published:2021-12-01

摘要/Abstract

摘要： 瘦素(leptin)是由控制各种生理过程的脂肪组织合成和分泌的一类激素,通过作用于靶细胞膜上的瘦素受体并经信号传导在各器官和系统中发挥一系列生物学效应。肾脏是高血压常见的靶器官之一。相关研究表明,瘦素在高血压肾损害中发挥作用,其机制可能与氧化应激及其炎症反应有关。本文以瘦素对高血压肾损害及其相关机制作一综述,并探讨瘦素对高血压肾损害发病机制研究进展。

关键词: 瘦素, 瘦素抵抗, 高血压, 肾损害, 氧化应激

Abstract: Leptin which is a kind of synthesis and secretion of hormone that participates in various physiological processes is the role of the leptin receptor on the target cell membrane and the signal transduction through a series of biological effects in different organs and systems. Kidney is one of the common target organs of hypertension, and related research shows that leptin plays a role in hypertensive kidney damage, whose mechanism may be related to oxidative stress and its inflammatory reaction. The paper reviewed leptin on renal damage in hypertension and its related mechanisms, to explore the leptin on renal pathogenesis of hypertension research progress.

Key words: Leptin, Leptin resistance, Hypertension, Renal damage, Oxidative stress

赵位昆, 徐彤彤, 胡迪聃, 张向宇, 吕祥威. 瘦素对高血压肾损害相关机制的研究进展[J]. 广州医药, 2018, 49(1): 110-113.

ZHAO Weikun, XU Tongtong, HU Didan, ZHANG Xiangyu, LV Xiangwei. Advances in research on the mechanism of leptin on hypertensive renal damage[J]. Guangzhou Medical Journal, 2018, 49(1): 110-113.

参考文献

[1] RODRIGUEZ-ITURBE B, PONS H, JOHNSON R J. Role of the Immune system in hypertension[J]. Physiol Rev,2017, 97(3): 1127-1164.
[2] MCMASTER W G, KIRABO A, MADHUR M S, et al. Inflammation, immunity, and hypertensive end-organ damage[J]. Circ Res, 2015, 116(6): 1022-1033.
[3] LA RUSSA D, BRUNELLI E, PELLEGRINO D. Oxidative imbalance and kidney damage in spontaneously hypertensive rats: activation of extrinsic apoptotic pathway[J]. Clin Sci (Lond), 2017, 131(13): 1419-1428.
[4] MORAES-VIEIRA P M, LAROCCA R A, BASSI E J, et al. Leptin deficiency impairs maturation of dendritic cells and enhances induction of regulatory T and Th17 cells[J]. Eur J lmmunol, 2014, 44(3):794-806.
[5] FOLCH J, PEDROS I, PATRACA I, et al. Neuroprotective and anti-ageing role of leptin[J]. J Mol Endocrinol, 2012, 49(3): 149-156.
[6] MUNZBERG H, MORRISON C D.Structure, production and signaling of leptin[J]. Metabolism, 2015, 64(1): 13-23.
[7] ARAGONES G, ARDID-RUIZ A, IBARS M, et al. Modulation of leptin resistance by food compound[J]. Mol Nutr Food Res, 2016, 60(8): 1789-1803.
[8] MARK A L. Selective Leptin resistance revisited[J]. Am J Physiol Regul Integr Comp Physiol, 2013, 305(6): 8566-8581.
[9] XUE H, WANG J L, HOU J H, et al. Prehypertension and chronic kidney disease in chinese population: four-year follow-up study[J]. PLoS One,2015, 10(12): e0144438.
[10] KOVESDY C P, FURTH S L, ZOCCALI C, et al. Obesity and kidney disease: Hidden consequences of the epidemic[J]. J Ren Care, 2017, 43(1): 3-10.
[11] DAS UN. Renin-angiotensin-aldosterone system in insulin resistance and metabolic syndrome[J]. J Transl Int Med, 2016, 4(2): 66-72.
[12] HAMED E A, ZAKAIY M M, AHMED N. et al. Circulating leptin and insulin in obese patients with and without type 2 diabetes mellitus: relation to ghrelin and oxidative steess[J]. D iabetes Res Clip Pract, 2011, 94(3):434-441.
[13] SINHA N, DABLA P K. Oxidative stress and antioxidants in hypertension-a current review[J]. Curr Hypertens Rev,2015, 11(2): 132-142.
[14] STEFANOVIC A, KOTUR-STEVULJEVIC J, SPASIC S,et al. The influence of obesity on the oxidative stress status and the concentration of leptin in type 2 diabetes mellitus patients[J]. Diabetes Res Clin Pract,2008, 79(1): 156-163.
[15] KWON H, PESSIN J E. Adipokines mediate inflammation and insulin resistance[J]. Front Endocrinol(Lausanne), 2013, 4(71):71.
[16] TIAN G, LIANG J H, WANG Z Y, et al. Emerging role of leptin in rheumatoid arthritis[J]. Clin Exp Immunol, 2014, 177(3): 557-570.
[17] GOTO K, KANEKO Y, SATO Y,et al. Leptin deficiency down-regulates IL-23 production in glomerular podocytes resulting in an attenuated immune response in nephrotoxic serum nephritis[J]. Int Immunol, 2016, 28(4): 197-208.
[18] DING N, LIU B, SONG J, et al. Leptin promotes endothelial dysfunction in chronic kidney disease through AKT/GSK3β and β-catenin signals[J]. Biochem Biophys Res Commun, 2016, 480(4): 544-551.
[19] ROGOBETE A F, SANDESC D, PAPURICA M, et al. The influence of metabolic imbalances and oxidative stress on the outcome of critically ill polytrauma patients: a review[J]. Burns Trauma, 2017, 5(1): 8.
[20] BOILAN E, WINANT V, DUMORTIER E, et al. Role of p38MAPK and oxidative stress in copper-induced senescence[J]. AGE, 2013, 35(6): 2255-2271.
[21] KAMATO D, BURCH M L, PIVA T J, et al. Transforming growth factor-β signalling: role and consequences of Smad linker region phosphorylation[J]. Cell Signal, 2013, 25(10): 2017-2024.
[22] MARTINEZ-USEROS J, LI W, CABEZA-MORALES M, et al. Oxidative stress: a new target for pancreatic cancer prognosis and treatment[J]. J Clin Med, 2017, 6(3): 29.
[23] YAO J, KE Z, WANG X, et al. Epithelial-mesenchymal transition and apoptosis of renal tubular epithelial cells are associated with disease progression in patients with IgA nephropathy[J]. Mol Med Rep, 2014, 10(1): 39-44.
[24] HE P, LI D, ZHANG B. Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy[J]. Mol Med Rep, 2014, 10(2): 638-644.
[25] AGHARAZII M, ST-LOUIS R, GAUTIER-BASTIEN A, et al. Inflammatory cytokines and reactive oxygen species as mediators oI chronic kidney disease-related vascular calcflication[J]. Am J Hypertens, 2015, 28(6): 746-755.
[26] KRISHNAN S M, SOBEY C G, LATZ E, et al. IL-1β and IL-18: inflammatory markers or mediators of hypertension? [J]. Br J Pharmacol,2014, 171(24): 5589-5602.
[27] SALEH MA, NORLANDER A E, MADHUR M S. Inhibition of interleukin 17-a but not interleukin-17f signaling lowers blood pressure and reduces end-organ inflammation in angiotensin ii-induced hypertension[J]. JACC Basic Transl Sci,2016, 1(7): 606-616.

瘦素对高血压肾损害相关机制的研究进展

Advances in research on the mechanism of leptin on hypertensive renal damage

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何同林, 何兰, 刘俊, 刘俊华, 阮宪东, 朱艳红. 高通量透析模式对改善维持性血液透析患者β2微球蛋白清除率及高血压的影响[J]. 广州医药, 2021, 52(5): 35-39.
[2]	翟子敬, 秦文娟, 王臻, 郭雪婷, 王忠, 芦桂林. 探讨肺动脉高压大鼠心肌损伤与氧化应激损伤的相关性研究[J]. 广州医药, 2021, 52(1): 1-5.
[3]	易杭, 徐启钟, 陈桢昌, 欧仲越, 谢晓桐, 黄乐琪, 朱晓琴. 香芹酚的解酒护肝作用的研究[J]. 广州医药, 2021, 52(1): 18-21.
[4]	钟雄东. 丹参有效成分——二氢丹参酮Ⅰ抑制胃癌的作用研究[J]. 广州医药, 2020, 51(6): 11-18.
[5]	刘景, 张月月. 蒜氨酸对血管性痴呆大鼠脑损伤的作用及机制研究[J]. 广州医药, 2020, 51(2): 99-102.
[6]	刘剑波. 神经内镜和常规开颅手术治疗高血压脑出血的优劣分析[J]. 广州医药, 2018, 49(6): 37-39.
[7]	银孟卓, 卢建文. 血浆chemerin水平与原发性高血压合并永久性心房纤颤的相关性研究[J]. 广州医药, 2018, 49(4): 13-16.
[8]	陈露丝, 岳晓军, 李韶南, 陈平安, 冯开薇, 吕何锦, 刘震. 社区综合防治合作模式对基层高血压病患者的药物经济学评价[J]. 广州医药, 2018, 49(4): 24-29.
[9]	邓聪, 张艳红, 岑美婷, 蔡敬宙, 赖艳娴, 杨志敏. 平胃散联合耳穴对单纯性肥胖的临床疗效及对血清NPY和Leptin的影响[J]. 广州医药, 2018, 49(3): 19-22.
[10]	肖媚, 李文礼, 罗伟汀. 丹参酮ⅡA磺酸钠不同时点给药在高血压性脑出血治疗中的疗效及对神经保护作用[J]. 广州医药, 2018, 49(3): 91-93.
[11]	黎艳芳, 关天旺, 图提古丽·麦麦提, 阿不都热西提·则亚维丁, 刘城. 新疆疏附县人民医院心脑血管疾病发病趋势及高血压危险因素分析[J]. 广州医药, 2018, 49(2): 33-37.
[12]	蔡胜业. 硝苯地平与厄贝沙坦联合治疗青年原发性高血压的临床效果分析[J]. 广州医药, 2016, 47(1): 97-98.
[13]	曾秀梅, 刘丰. 社区老年高血压病人直立性低血压的药物影响研究[J]. 广州医药, 2015, 46(5): 84-85.
[14]	罗文辉, 陈建平, 李金连, 李国文, 李莉珊. D-二聚体、超敏C反应蛋白在年轻原发性高血压病患者血清中的表达及相关性研究[J]. 广州医药, 2015, 46(4): 32-33.
[15]	赖艳娴, 郭宝云, 邓聪, 阿不都热西提·则亚维丁, 刘城, 陈文忠, 刘凯. 新疆维吾尔族、汉族原发性高血压患者ACE多态性分析[J]. 广州医药, 2015, 46(3): 12-15.